The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

BANDAR SERI BEGAWAN: The Ministry of Health (MoH) has introduced the pneumococcal conjugate vaccine (PCV) into Brunei Darussalam’s Expanded Programme on Immunisation, effective FeB 1 as part of ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

The ensuing tissue damage is integral to pneumococcal disease (22). For example, in the lung, exacerbated inflammation promotes tissue invasion and systemic spread (21, 23). In contrast, at the ...

Wierzbowski A, Pless R, Hildebrand KJ on behalf of the National Advisory Committee on Immunization (NACI). Summary of the NACI Statement on Public Health Level Recommendations on the Use of ...

Bacterial pneumonia is most commonly caused by a bacteria called Streptococcus pneumoniae which accounts for around 50% of cases. Other common causes include Haemophilus influenzae, Chlamydia ...